Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1016/j.expneurol.2016.06.015

http://scihub22266oqcxt.onion/10.1016/j.expneurol.2016.06.015
suck pdf from google scholar
27317297!5240152!27317297
unlimited free pdf from europmc27317297    free
PDF from PMC    free
html from PMC    free

Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27317297&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215

suck abstract from ncbi

pmid27317297      Exp+Neurol 2016 ; 283 (Pt A): 151-6
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Extended therapeutic window of a novel peptide inhibitor of TRPM2 channels following focal cerebral ischemia #MMPMID27317297
  • Shimizu T; Dietz RM; Cruz-Torres I; Strnad F; Garske AK; Moreno M; Venna VR; Quillinan N; Herson PS
  • Exp Neurol 2016[Sep]; 283 (Pt A): 151-6 PMID27317297show ga
  • INTRODUCTION: TRPM2 channels have been suggested to play a role in ischemic neuronal injury, specifically in males. A major hindrance to TRPM2 research has been the lack of specific TRPM2 inhibitors. The current study characterized the specificity and neuroprotective efficacy of a novel TRPM2 inhibitor. METHODS: Fluorescent calcium imaging (Fluo5F) was used to determine inhibitor efficacy of the TRPM2 peptide inhibitor (tat-M2NX) in HEK293 cells stably expressing hTRPM2. Adult (2-3months) and aged (18-20months) mice were subjected to 60min middle cerebral artery occlusion (MCAO) and injected with tat-M2NX, control scrambled peptide (tat-SCR) or clotrimazole (CTZ) either 20min prior or 3h after reperfusion. Infarct size was assessed using TTC staining. RESULTS: TRPM2 inhibition by tat-M2NX was observed by decreased Ca(2+) influx following H2O2 exposure human TRPM2 expressing cells. Male mice pre-treated with tat-M2NX had smaller infarct volume compared to tat-SCR. No effect of tat-M2NX on infarct size was observed in female mice. Importantly, male TRPM2(-/-) mice were not further protected by tat-M2NX, demonstrating selectivity of tat-M2NX. Administration of tat-M2NX 3h after reperfusion provided significant protection to males when analyzed at 24h or 4days after MCAO. Finally, we observed that tat-M2NX reduced ischemic injury in aged male mice. CONCLUSIONS: These data demonstrate the development of a new peptide inhibitor of TRPM2 channels that provides protection from ischemic stroke in young adult and aged male animals with a clinically relevant therapeutic window.
  • |Age Factors[MESH]
  • |Animals[MESH]
  • |Brain Infarction/drug therapy/etiology[MESH]
  • |Brain Ischemia/complications/*drug therapy[MESH]
  • |Disease Models, Animal[MESH]
  • |Dose-Response Relationship, Drug[MESH]
  • |Female[MESH]
  • |HEK293 Cells/drug effects/metabolism[MESH]
  • |Humans[MESH]
  • |Male[MESH]
  • |Mice[MESH]
  • |Mice, Knockout[MESH]
  • |Neuroprotective Agents/*therapeutic use[MESH]
  • |Peptides/*therapeutic use[MESH]
  • |Sex Factors[MESH]
  • |TRPM Cation Channels/*chemistry/genetics/*metabolism[MESH]
  • |Time Factors[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box